CC BY-NC-ND 4.0 · Thromb Haemost 2024; 124(02): 152-162
DOI: 10.1055/a-2107-0815
Stroke, Systemic or Venous Thromboembolism

Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

Dongwon Yoon
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
Han Eol Jeong
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
Songhwa Choi
3   Medical Affairs, Pfizer Korea Ltd., Seoul, South Korea
Ju-Young Shin
1   School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2   Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
4   Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
Soo-Mee Bang
5   Division of Hemato-Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
› Author Affiliations


Background Venous thromboembolism (VTE) is associated with increased morbidity, mortality, and health care expenditure. However, the comprehensive utilization of anticoagulation therapy in patients with VTE, especially regarding active cancer, in real-world practice remains unclear.

Objective To describe the prescription, persistence, and patterns of anticoagulation therapy among patients with VTE stratified according to active cancer.

Methods Using Korean nationwide claims data, we identified an incident, treatment-naïve cohort of patients with VTE from 2013 to 2019 and classified them according to the presence/absence of active cancer. We explored the secular trends, treatment patterns (e.g., discontinuation, interruption, and switch), and persistence of anticoagulation therapy.

Results There were 48,504 and 7,255 patients without and with active cancer, respectively. Non-vitamin K antagonist oral anticoagulants (NOACs) were the most common anticoagulant in both groups (65.1 and 57.9%, respectively). The prescription of NOACs increased steeply over time, regardless of active cancer, whereas parenteral anticoagulants (PACs) plateaued and warfarin decreased sharply. A heterogeneous pattern was observed between the groups without and with active cancer (3-month persistence was 60.8, 62.9, 57.2, and 3.4%, respectively; 6-month persistence was 42.3, 33.5, 25.9, and 1.2% vs. 9.9%). Median durations of continuous anticoagulant therapy for warfarin, NOAC, and PAC were 183, 147, and 3 days in nonactive cancer patients, and 121, 117, and 44 days in active cancer patients.

Conclusion Our findings suggest that there were substantial differences in persistence, patterns, and patient characteristics of anticoagulant therapy based on index anticoagulant and active cancer.

Supplementary Material

Publication History

Received: 20 December 2022

Accepted: 22 May 2023

Accepted Manuscript online:
07 June 2023

Article published online:
15 July 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388 (10063): 3060-3073
  • 2 Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of venous thromboembolism in asian populations: a systematic review. Thromb Haemost 2017; 117 (12) 2243-2260
  • 3 Kim HY, Chang SA, Kim KH. et al; Venous Thromboembolism Research Group of Korean Society of Echocardiography. Epidemiology of venous thromboembolism and treatment pattern of oral anticoagulation in Korea, 2009-2016: a nationwide study based on the national health insurance service database. J Cardiovasc Imaging 2021; 29 (03) 265-278
  • 4 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
  • 5 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
  • 6 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
  • 7 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
  • 8 Farge D, Bounameaux H, Brenner B. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 (10) e452-e466
  • 9 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
  • 10 Lyman GH, Bohlke K, Khorana AA. et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
  • 11 Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119 (01) 60-68
  • 12 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
  • 13 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
  • 14 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
  • 15 Streiff MB, Holmstrom B, Angelini D. et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19 (10) 1181-1201
  • 16 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
  • 17 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38 (05) 496-520
  • 18 Bang SM, Kang JH, Hong MH. et al. Treatment patterns and clinical outcomes in Korean cancer patients with venous thromboembolism: a retrospective cohort study. Clin Appl Thromb Hemost 2021; 27: 1076029620979575
  • 19 Haas S, Ageno W, Weitz JI. et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost 2019; 17 (10) 1694-1706
  • 20 Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017; 32 (05) 718-728
  • 21 Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017. Res Pract Thromb Haemost 2019; 3 (04) 668-673
  • 22 Sindet-Pedersen C, Pallisgaard JL, Staerk L. et al. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - a Danish nationwide cohort study. Sci Rep 2017; 7 (01) 3347
  • 23 Lee CH, Fang CC, Tsai LM. et al. Changing treatment patterns in patients with venous thromboembolism in Taiwan. Circ J 2020; 84 (02) 283-293
  • 24 Ghanima W, Schultze A, Donaldson R. et al. Oral anticoagulation therapy for venous thromboembolism in norway: time trends and treatment patterns. Clin Ther 2021; 43 (07) 1179.e3-1190.e3
  • 25 Wilke T, Meinecke AK, Schaefer B, Buchwald S, Eriksson D, Müller S. Patient preferences for nonvitamin K antagonist oral anticoagulants in stroke prevention: a multicountry discrete choice experiment. Cardiol Res Pract 2019; 2019: 5719624
  • 26 Kim SA, Lee JH, Lee JY. et al. Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study. Thromb Haemost 2022; 122 (12) 2011-2018
  • 27 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
  • 28 Hong J, Ahn SY, Lee YJ. et al; Korean Society of Hematology Thrombosis and Hemostasis Working Party. Updated recommendations for the treatment of venous thromboembolism. Blood Res 2021; 56 (01) 6-16
  • 29 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
  • 30 Delate T, Charlu M, Zhu S. et al. Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thromb Res 2020; 196: 367-370
  • 31 Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med 2022; 175 (01) 20-28
  • 32 Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 2019; 6 (01) e20-e28
  • 33 Vora P, Soriano-Gabarró M, Suzart K, Persson Brobert G. Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies. Patient Prefer Adherence 2016; 10: 1657-1665
  • 34 Haastrup SB, Hellfritzsch M, Rasmussen L, Pottegård A, Grove EL. Use of non-vitamin K antagonist oral anticoagulants 2008-2016: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol 2018; 123 (04) 452-463
  • 35 Schaefer JK, Li M, Wu Z. et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost 2021; 19 (01) 212-220
  • 36 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850